IN2014DN00200A - - Google Patents
Info
- Publication number
- IN2014DN00200A IN2014DN00200A IN200DEN2014A IN2014DN00200A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A IN 200DEN2014 A IN200DEN2014 A IN 200DEN2014A IN 2014DN00200 A IN2014DN00200 A IN 2014DN00200A
- Authority
- IN
- India
- Prior art keywords
- riluzole
- subject
- methods
- reducing
- auc24h
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161507381P | 2011-07-13 | 2011-07-13 | |
US201161544533P | 2011-10-07 | 2011-10-07 | |
US201261637770P | 2012-04-24 | 2012-04-24 | |
US201261637759P | 2012-04-24 | 2012-04-24 | |
US201261646699P | 2012-05-14 | 2012-05-14 | |
PCT/US2012/046523 WO2013010015A2 (en) | 2011-07-13 | 2012-07-12 | Combination als therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN00200A true IN2014DN00200A (el) | 2015-06-05 |
Family
ID=47506929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN200DEN2014 IN2014DN00200A (el) | 2011-07-13 | 2012-07-12 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10272082B2 (el) |
EP (1) | EP2731611B1 (el) |
JP (2) | JP6145946B2 (el) |
KR (1) | KR101951220B1 (el) |
CN (2) | CN104039148A (el) |
AU (2) | AU2012281042B2 (el) |
BR (1) | BR112014000742A2 (el) |
CA (1) | CA2849213A1 (el) |
EA (2) | EA201791043A1 (el) |
HK (1) | HK1197178A1 (el) |
IL (1) | IL230391B (el) |
IN (1) | IN2014DN00200A (el) |
SG (1) | SG10201605707UA (el) |
WO (1) | WO2013010015A2 (el) |
ZA (1) | ZA201400236B (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
US20160263110A1 (en) * | 2013-11-04 | 2016-09-15 | Ab Science | Use of masitinib for treatment of amyotrophic lateral sclerosis |
HRP20220183T1 (hr) | 2014-04-29 | 2022-04-29 | Cytokinetics, Inc. | Postupci smanjivanja propadanja vitalnog kapaciteta |
EA038518B1 (ru) * | 2014-11-21 | 2021-09-09 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Сублингвальный препарат рилузола |
CN107735077A (zh) * | 2014-11-21 | 2018-02-23 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
CN108883108B (zh) | 2016-03-25 | 2021-08-06 | Ab科学有限公司 | 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 |
CA3151459A1 (en) * | 2019-09-20 | 2021-03-25 | Ana PEREIRA | Controlled release formulations of riluzole and their uses |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
IT1156732B (it) | 1978-05-10 | 1987-02-04 | Roussel Maestretti Spa | Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione |
US4668686A (en) | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
US4775674A (en) | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
US5354759A (en) | 1991-09-12 | 1994-10-11 | Fujisawa Pharmaceutical Co., Ltd. | Angiotenin II antagonizing heterocyclic compounds |
JPH0641135A (ja) | 1992-07-21 | 1994-02-15 | Nippon Soda Co Ltd | イミダゾプテリジン誘導体及びその製造方法 |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
SK18542000A3 (sk) | 1998-06-04 | 2001-12-03 | Abbott Laboratories | Protizápalové zlúčeniny inhibujúce bunkovú adhéziu |
JP2003511456A (ja) | 1999-10-08 | 2003-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二環状イミダゾ−5−イル−アミン誘導体 |
BR0014818A (pt) | 1999-10-08 | 2002-06-18 | Gruenenthal Gmbh | Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica |
DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
US20040235801A1 (en) * | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
US20030083318A1 (en) | 2001-10-25 | 2003-05-01 | Jean-Pierre Julien | Therapy for neurodegenerative diseases |
GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
GB0212048D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
WO2004043913A2 (en) | 2002-11-08 | 2004-05-27 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
AU2004263080B2 (en) | 2003-06-26 | 2008-12-18 | Merck Sharp & Dohme Corp. | Benzodiazepine CGRP receptor antagonists |
EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
MXPA06007054A (es) | 2003-12-19 | 2007-04-17 | Elixir Pharmaceuticals Inc | Metodos para tratar una enfermedad. |
WO2005072412A2 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc. | Anti-viral therapeutics |
WO2005108374A1 (en) | 2004-04-29 | 2005-11-17 | Fmc Corporation | Insecticidal diazole and triazole derivatives |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
JP2008530212A (ja) | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有するピペラジン−ピペリジン |
WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
DK3421471T3 (da) | 2006-04-25 | 2021-06-14 | Astex Therapeutics Ltd | Purin- og deazapurinderivater som farmaceutiske forbindelser |
JP2009536620A (ja) | 2006-04-25 | 2009-10-15 | アステックス、セラピューティックス、リミテッド | 医薬組み合わせ物 |
US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
US20100173930A1 (en) | 2006-08-01 | 2010-07-08 | Alex Muci | Certain Chemical Entities, Compositions and Methods |
CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
PT2583970E (pt) * | 2006-08-02 | 2016-02-08 | Cytokinetics Inc | Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
KR20140104060A (ko) | 2006-10-19 | 2014-08-27 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
WO2008075007A1 (en) | 2006-12-21 | 2008-06-26 | Cancer Research Technology Limited | Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents |
BRPI0806898A2 (pt) | 2007-01-19 | 2015-07-14 | Ardea Biosciences Inc | Inibidores de mek |
EP2139478A4 (en) | 2007-03-30 | 2010-05-05 | Cytokinetics Inc | CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
EP2018854A1 (en) | 2007-07-27 | 2009-01-28 | Merz Pharma GmbH & Co. KGaA | Novel combinations of neramexane for the treatment of neurodegenerative disorders |
EP2244711A4 (en) | 2008-02-04 | 2011-08-24 | Cytokinetics Inc | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS |
US7998976B2 (en) | 2008-02-04 | 2011-08-16 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
CA2730473A1 (en) | 2008-07-11 | 2010-01-14 | Glaxo Group Limited | Novel treatment |
AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
EP2228054A1 (en) | 2009-03-13 | 2010-09-15 | ITALFARMACO S.p.A. | Riluzole aqueous suspensions |
MX2011013577A (es) * | 2009-06-19 | 2012-04-10 | Knopp Neurosciences Inc | Composiciones y metodos para tratar esclerosis lateral amiotrofica. |
SG11201406270YA (en) | 2012-04-02 | 2014-10-30 | Cytokinetics Inc | Methods for improving diaphragm function |
EP2836590A4 (en) | 2012-04-11 | 2016-04-13 | Cytokinetics Inc | METHOD FOR IMPROVING THE RESISTANCE TO SKELETON MUSCULAR FEEDING |
HRP20220183T1 (hr) | 2014-04-29 | 2022-04-29 | Cytokinetics, Inc. | Postupci smanjivanja propadanja vitalnog kapaciteta |
-
2012
- 2012-07-12 EA EA201791043A patent/EA201791043A1/ru unknown
- 2012-07-12 IN IN200DEN2014 patent/IN2014DN00200A/en unknown
- 2012-07-12 CN CN201280034661.5A patent/CN104039148A/zh active Pending
- 2012-07-12 EA EA201490011A patent/EA028060B1/ru not_active IP Right Cessation
- 2012-07-12 US US14/131,649 patent/US10272082B2/en not_active Expired - Fee Related
- 2012-07-12 SG SG10201605707UA patent/SG10201605707UA/en unknown
- 2012-07-12 CA CA2849213A patent/CA2849213A1/en not_active Abandoned
- 2012-07-12 KR KR1020147000783A patent/KR101951220B1/ko active IP Right Grant
- 2012-07-12 JP JP2014520335A patent/JP6145946B2/ja not_active Expired - Fee Related
- 2012-07-12 CN CN201811116043.0A patent/CN109316480A/zh active Pending
- 2012-07-12 AU AU2012281042A patent/AU2012281042B2/en not_active Ceased
- 2012-07-12 EP EP12811325.5A patent/EP2731611B1/en active Active
- 2012-07-12 WO PCT/US2012/046523 patent/WO2013010015A2/en active Application Filing
- 2012-07-12 BR BR112014000742A patent/BR112014000742A2/pt not_active Application Discontinuation
-
2014
- 2014-01-09 IL IL230391A patent/IL230391B/en active IP Right Grant
- 2014-01-10 ZA ZA2014/00236A patent/ZA201400236B/en unknown
- 2014-10-22 HK HK14110537A patent/HK1197178A1/xx unknown
-
2016
- 2016-10-13 AU AU2016244263A patent/AU2016244263A1/en not_active Abandoned
-
2017
- 2017-04-28 JP JP2017090313A patent/JP2017128610A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112014000742A2 (pt) | 2016-08-23 |
EA201791043A1 (ru) | 2017-09-29 |
HK1197178A1 (en) | 2015-01-09 |
CA2849213A1 (en) | 2013-01-17 |
JP2017128610A (ja) | 2017-07-27 |
WO2013010015A2 (en) | 2013-01-17 |
JP2014520856A (ja) | 2014-08-25 |
US20140243344A1 (en) | 2014-08-28 |
EP2731611B1 (en) | 2019-09-18 |
WO2013010015A3 (en) | 2014-05-15 |
EP2731611A4 (en) | 2015-02-18 |
CN104039148A (zh) | 2014-09-10 |
EA201490011A1 (ru) | 2014-08-29 |
EA028060B1 (ru) | 2017-10-31 |
AU2016244263A1 (en) | 2016-11-03 |
CN109316480A (zh) | 2019-02-12 |
NZ619924A (en) | 2016-02-26 |
AU2012281042B2 (en) | 2016-07-14 |
KR20140074270A (ko) | 2014-06-17 |
IL230391B (en) | 2019-03-31 |
US10272082B2 (en) | 2019-04-30 |
ZA201400236B (en) | 2014-10-29 |
AU2012281042A1 (en) | 2014-01-30 |
SG10201605707UA (en) | 2016-09-29 |
EP2731611A2 (en) | 2014-05-21 |
KR101951220B1 (ko) | 2019-02-22 |
JP6145946B2 (ja) | 2017-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN00200A (el) | ||
MX365950B (es) | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. | |
MY196418A (en) | Therapeutically Active Compounds and Their Methods of use | |
GB201016812D0 (en) | Method and apparatus for treating respiratory diesease | |
WO2012093258A3 (en) | Irf5- related treatment and screening | |
MX2014004548A (es) | Metodos para tratar pacientes pediatricos usando dexmedetomidina. | |
MX350666B (es) | Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia. | |
MX2014000515A (es) | Metodo de tratamiento de inflamacion e himpertencion secuestrante de gama -cetoaldehido. | |
EA201490614A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-kB | |
EA201391591A1 (ru) | Лечение множественной миеломы | |
MX2015003035A (es) | Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual. | |
NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
MX2015004389A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods. | |
MX2013008715A (es) | Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco. | |
MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
CA2866819C (en) | Method for treating inflammation | |
NZ597115A (en) | Method of treating age related disorders with fujimycin | |
MX2010013790A (es) | Composiciones y metodos para tratar inflamacion de corneas. | |
MX2014013503A (es) | Metodo para inducir actividad udp-glucuronosiltransferasa utilizando pterostilbeno. | |
WO2008129239A3 (en) | Use of agents that inhibit homologous recombination for the treatment of cancer | |
MX2014006990A (es) | Tratamiento para diabetes tipo i y tipo ii. | |
UA67100U (ru) | Способ лечения переднего эндогенного увеита | |
MX2022002947A (es) | Avocatina b para el tratamiento de enfermedades y afecciones. | |
WO2011139368A3 (en) | Methods of treatment of inflammatory diseases | |
IN2014DN05769A (el) |